What is the latest EMCURE stock price?
The latest stored price for EMCURE is Rs 1,863.00 as of 2026-08-21.
gimli
EMCURE stock AI analysis
EMCURE Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
EMCURE PHARMACEUTICALS L is a small-cap stock in Healthcare. This Gimli page shows the latest available EMCURE price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹1,863.00
1W return
-3.59%
1M return
-3.20%
3M return
+6.37%
6M return
+29.56%
1Y return
+26.73%
Market cap
₹35,320.52 cr
PE
38.50
PB
7.10
ROE
+19.08%
ROCE
+25.30%
RSI
43.01
Turnover
₹23.27 cr
Why it can matter in screens
- Momentum: EMCURE is below 50DMA, above 200DMA; RSI is 43.01.
- Returns: 1D -0.98%, 1W -3.59%, 1M -3.20%, 3M +6.37%, 1Y +26.73%.
- Trend levels: 52W high ₹2,048.00, 52W low ₹1,667.00, off high -9.03%.
- Liquidity: latest turnover is ₹23.27 cr; volume vs 20D is +0.77%.
- Valuation/profitability: PE 38.50, PB 7.10, ROE +19.08%, ROCE +25.30%.
- Growth: 3Y sales CAGR +15.77%, 3Y profit CAGR +20.21%.
Quick Answers
Is EMCURE above its 50DMA and 200DMA?
EMCURE is below 50DMA, above 200DMA. The latest 50DMA is 1,864.62 and the latest 200DMA is 1,606.26.
What are EMCURE PE, ROE and ROCE?
EMCURE has PE 38.50, ROE +19.08%, and ROCE +25.30% in Gimli's latest available snapshot.
How has EMCURE performed recently?
EMCURE has returned -3.20% over 1 month, +6.37% over 3 months, and +26.73% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 1,475.96 cr | 364.62 cr | 200.11 cr | 15.50 |
| 2026-03-31 | 2,469.70 cr | 493.84 cr | 243.40 cr | 12.84 |
| 2025-12-31 | 2,363.48 cr | 456.45 cr | 230.54 cr | 12.16 |
| 2025-09-30 | 2,269.82 cr | 478.60 cr | 243.46 cr | 12.85 |
| 2025-06-30 | 2,100.54 cr | 416.97 cr | 206.95 cr | 10.92 |
| 2025-03-31 | 2,116.24 cr | 396.48 cr | 188.96 cr | 9.97 |
| 2024-12-31 | 1,962.63 cr | 358.50 cr | n/a | nan |
| 2024-09-30 | 2,001.98 cr | 416.53 cr | 194.57 cr | 10.33 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 9,203.54 cr | 1,845.86 cr | 924.36 cr | 48.77 |
| 2025-03-31 | 7,896.00 cr | 1,531.31 cr | 681.33 cr | 36.43 |
| 2024-03-31 | 6,581.99 cr | 1,240.33 cr | 498.18 cr | 27.57 |
| 2023-03-31 | 5,931.08 cr | 1,170.25 cr | 532.02 cr | 29.43 |
| 2022-03-31 | 3,519.92 cr | 1,349.87 cr | 446.81 cr | 24.71 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 9,612.48 cr | 136.66 cr | 1,521.24 cr | 4,976.67 cr |
| 2025-03-31 | 8,232.72 cr | 121.82 cr | 1,022.75 cr | 4,641.55 cr |
| 2024-03-31 | 7,806.16 cr | 108.96 cr | 2,334.97 cr | 3,121.76 cr |
| 2023-03-31 | 6,672.53 cr | 56.37 cr | 2,334.30 cr | 2,649.66 cr |
| 2022-03-31 | 6,063.47 cr | 76.02 cr | 2,217.20 cr | 2,114.14 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 943.54 cr | 395.86 cr | n/a |
| 2025-03-31 | 851.71 cr | 444.78 cr | n/a |
| 2024-03-31 | 1,097.24 cr | 790.11 cr | n/a |
| 2023-03-31 | 746.85 cr | 343.49 cr | n/a |
| 2022-03-31 | 768.21 cr | 371.22 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +77.83% | +4.88% | +8.46% | +6.87% | +8.83% | +0.04% |
| 2026-03-31 | +77.87% | +3.35% | +6.10% | +4.94% | +12.68% | +0.04% |
| 2025-12-31 | +77.87% | +3.59% | +6.10% | +4.83% | +12.44% | +0.04% |
| 2025-09-30 | +77.88% | +3.29% | +4.37% | +3.58% | +14.46% | +0.04% |
| 2025-06-30 | +77.91% | +2.86% | +2.84% | +2.34% | +16.39% | +0.04% |
| 2025-03-31 | +77.92% | +3.07% | +3.44% | +2.73% | +15.57% | +0.04% |
| 2024-12-31 | +77.94% | +3.05% | +3.87% | +3.10% | +15.14% | +0.00% |
| 2024-09-30 | +78.08% | +2.91% | +3.96% | +3.30% | +15.05% | +0.00% |
| 2024-07-08 | +78.08% | +1.76% | +3.34% | +1.77% | +16.82% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze EMCURE PHARMACEUTICALS L with valuation, momentum and industry peers
- Compare EMCURE with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare EMCURE with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.